New drug cocktail targets Hard-to-Treat cancers
NCT ID NCT07318649
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 study tests two oral drugs, GH21 and D-1553, in 120 adults with advanced solid tumors that have a specific mutation called KRASG12C. Participants have already tried other treatments without success. The goal is to see if the combination can shrink tumors and control the disease. The study is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GH21 capsules and D-1553 tablets
What this could lead to
If successful, this combination could offer a new treatment option for people with KRASG12C-mutated cancers that have stopped responding to other therapies.
What could go wrong
This is an early Phase 2 trial with only 120 participants, so results may not apply to everyone. The drugs may cause side effects or fail to shrink tumors in many patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••